HOME >> MEDICINE >> NEWS
Positive results for ACRUX's lead product in US Phase 3 trial

Acrux (ASX: ACR), the pharmaceutical company with unique technology for delivering drugs through the skin, today announced positive results in a US Phase 3 clinical trial of Evamist, its daily skin spray for prevention of symptoms associated with menopause. The trial was conducted by its US commercial partner VIVUS Inc. (NASDAQ: VVUS), which will now proceed to file a marketing application with the US Food and Drug Administration (FDA) in the second half of 2006.

Evamist is the most advanced commercial application of Acrux's patented delivery technology; if the FDA approves VIVUS' marketing application, Acrux's first product could be available to women in the USA in the second half of 2007. Several other products that use the same delivery technology are following close behind. The positive result of this Phase 3 trial is therefore a pivotal milestone for each of these products.

The Phase 3 trial assessed the safety and efficacy of Evamist for the treatment of hot flushes in menopausal women. The trial was a 12-week study of 457 menopausal women, conducted under a Special Protocol Assessment (SPA) from the FDA. Results showed that the most effective Evamist dose decreased the number of hot flushes by 78%. The reduction in frequency and severity of moderate to severe hot flushes was statistically significant compared with placebo for all three doses of Evamist evaluated.

Importantly, application site irritation was less than 1% and was mild in nature. The results from the trial will be discussed by VIVUS at an Analyst Day in New York on 18 May 2006.

"We believe these positive trial results along with this novel patient-preferred transdermal delivery system will establish Evamist as a superior estrogen therapy for the treatment of menopausal symptoms," stated Leland Wilson, president and chief executive officer for VIVUS. "We have worked diligently toward the development of this unique and easy-to-use product, and we are thrilled with
'"/>

Contact: Igor Gonda
61-38-379-0100
Research Australia
9-May-2006


Page: 1 2

Related medicine news :

1. Positive results more likely from industry-funded breast cancer trials
2. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
3. Positive parenting helps encourage healthy sun habits in children
4. Positive outcome of Medicare drug benefit
5. Positive study results for methylphenidate transdermal system
6. Positive study results for methylphenidate transdermal system
7. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
8. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
9. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
10. Targeted, oral agent Enzastaurin shows favorable results
11. Childhood obesity intervention shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive results for ACRUX lead product Phase trial

(Date:2/27/2015)... Qualis Health, one of the nation’s ... a finalist in the 6th Annual Case In ... toward continuous improvement in care transitions. The nomination ... rates through its Communities for Safer Transitions of ... this national recognition, which demonstrates Qualis Health’s dedication ...
(Date:2/27/2015)... Wausau, WI (PRWEB) February 27, 2015 ... UP4 Adult Cubes, at Natural Products Expo West, March ... “We are very excited to release the hands down ... orange cream taste with an extra zing of Vitamin ... Kids Cubes, winner of the NutrAward 2014, Delicious Living’s ...
(Date:2/27/2015)... The purpose of the Rouche Graduate ... explore the current use of 3D printing in specific ... to the Survey about 3D Printing please go to ... among large and small companies from a wide variety ... PwC and Manufacturing Institute survey of 3D Printing use ...
(Date:2/27/2015)... Marketresearchreports.biz has announced the addition of a ... market studies that presents an analysis of the global ... The research report talks about the current market trends ... industry across the globe. , According to the market ... global sports medicine devices market is likely to develop ...
(Date:2/27/2015)... 2015 Available in select spas ... http://www.lespausa.com , Phytocéane introduces ... anti-aging collection. NIGHT RENEWAL CREAM reinforces the skin’s ... tightening the facial features with a unique fomulation ... restores the Klotho youth protein which in turn ...
Breaking Medicine News(10 mins):Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 3Health News:Global Sports Medicine Devices Market Benefitting from Significant Contribution from Arthroscopy Segment: MarketResearchReports.Biz 2Health News:Global Sports Medicine Devices Market Benefitting from Significant Contribution from Arthroscopy Segment: MarketResearchReports.Biz 3Health News:Phytocéane introduces NIGHT RENEWAL CREAM 2Health News:Phytocéane introduces NIGHT RENEWAL CREAM 3
(Date:2/26/2015)... 26, 2015 Every year many millions of ... heart disease.  Nevertheless, year after year doctors and the ... the first test to determine the status of heart ... or not, even though that technology is over 100 ... that doctors know, (while most patients do not know) ...
(Date:2/26/2015)... Feb. 26, 2015  Spring Bank Pharmaceuticals, Inc., ... the treatment of Hepatitis B virus (HBV) and ... a $22 million financing. Funds from this financing ... novel, broad spectrum antiviral agent derived from ... (SMNH) chemistry platform, into Phase II clinical trials ...
(Date:2/26/2015)... SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 ... of a Series A financing round totaling $20.4 million. ... and Third Point Ventures, includes participation by Aperture Venture ... company co-founded in 2013 by David Wurtman , ... M. Scott Harris , M.D., Chief Medical Officer.  In ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
Cached News: